Günter Höglinger
Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (26)
Year:
2026
Background Progressive Supranuclear Palsy (PSP) is a rare and severe neurodegenerative tauopathy characterized by diverse clinical phenotypes, including Richardson's syndrome (PSP‐RS), PSP‐parkinsonism (PSP‐P), PSP‐progressive gait freezing (PSP‐PGF), and PSP‐corticobasal syndrome (PSP‐CBS). Significant geographic variation exists in prevalence, clinical presentations, and prognosis. Objectives This global review aims to systematically evaluate the epidemiological variation, clinical phenotypes, diagnostic practices, and management strategies for PSP, focusing on regional disparities and identifying influencing genetic and environmental factors. Methodology A comprehensive literature search following PRISMA guidelines was conducted, analyzing studies reporting PSP epidemiology, phenotypes, diagnostic criteria, risk factors, treatments, and prognoses. Data were categorized into epidemiology, risk factors, clinical presentations, diagnosis, treatment accessibility, and outcomes, considering geographic variation. Results Global PSP prevalence ranges between 5–6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure. Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction. Prognosis significantly varies with subtype; PSP‐RS shows rapid progression and shorter survival (5–7 years), whereas PSP‐P has a milder clinical course (8–12 years). Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services. Diagnostic accuracy has improved with the adoption of MDS‐PSP criteria, facilitating recognition of diverse phenotypes. Conclusions Regional disparities in PSP prevalence, phenotypic presentation, and healthcare accessibility underscore the importance of standardized diagnostic criteria, targeted genetic and environmental studies, and equitable healthcare strategies. Enhanced global collaboration is essential for improving PSP diagnosis, management, and patient outcomes worldwide.
Year:
2026
Year:
2026
Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Cardiovascular autonomic failure is a frequent non-motor feature of Parkinson’s disease (PD) that affects up to one third of individuals from the premotor to the advanced stages of the disease, with major diagnostic, therapeutic and prognostic implications. It may manifest with orthostatic, post-prandial or exercise-induced hypotension, as well as hypertensive episodes in the supine position during wakefulness or nocturnal sleep. Hypotensive episodes may remain asymptomatic or manifest with symptoms of end-organ hypoperfusion in the upright position, after meals or during exertion that may include lightheadedness, blurred vision, cognitive slowness, shuffling gait, back pain, fatigue or, in severe cases, syncope. Supine and nocturnal hypertension are likewise often asymptomatic, yet may cause nocturnal polyuria, and disrupt sleep through frequent nocturnal toilet visits. Bedside screening for cardiovascular autonomic failure relies on targeted history taking, eventually supported by validated questionnaires, and supine to standing heart rate and blood pressure measurements. A more detailed assessment is obtained with cardiovascular autonomic function tests under continuous, non-invasive, hemodynamic monitoring, complemented by 24-hours ambulatory blood pressure monitoring and home blood pressure diaries. Hypotensive episodes are managed by addressing potential triggers, such as infections, anemia, dehydration and polypharmacy, followed by a stepwise implementation of behavioral, non-pharmacological and pharmacological strategies. Individuals with orthostatic hypotension should be constantly monitored for concomitant supine and nocturnal hypertension, especially if treatment with pressor agents has been recently started. Hypertensive episodes are likewise treated in a stepwise fashion with preventive, non-pharmacological and pharmacological measures, prioritizing hypotension control during daytime and mitigating hypertension overnight.
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (25)
David J. Pedrosa
-
Wolfgang Jost
head of neurology
Albert-Ludwigs-Universität Freiburg
Georg Kägi
Head of movement disorders center
University Hospital of Bern
Paul Krack
department of basic neuroscience university of geneva geneva switzerland
Stefan Lichtenthaler
Technical University of Munich
Mats Karlsson
Professor
Uppsala University
Alexander Pantelyat
Associate Professor
Johns Hopkins University
Said el Bouhaddani
assistant professor
University Medical Center Groningen
Matthias Brendel
-
Max Wühr
Independent Research Group Leader
Ludwig-Maximilians-Universität München
Karsten Witt
Professor (W3)
Carl von Ossietzky Universität Oldenburg
Praveen Thokala
Reader
University of York
Dragomir Milovanovic
University Professor
Charité - Universitätsmedizin Berlin
Martin Posch
Medical University of Vienna
Angelo Antonini
Full Professor
University of Padova
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Jochen Herms
Full professor
Ludwig-Maximilians-Universität München
Irene Litvan
Professor
University of California, San Diego
Anthony E. Lang
-
Gabor G. Kovacs
University of Toronto
Shijie Ren
University of Sheffield
Klaus Jahn
Senior Researcher
Ludwig-Maximilians-Universität München
Björn H. Falkenburger
Academic Staff
Technische Universität Dresden
Piero Parchi
Professore Associato di Neurologia
University of Bologna
jean-christophe corvol
Professor of Neurology
Sorbonne Université Campus Pierre et Marie Curie
Make your next move.
Prepare your application
Review drafts before you send them.